Startpage News
Startpage

News

1
MAR
2019

Latvian Biomedical Research and Studies Centre launches new project "Understanding the biology of the minimal residual disease after targeted therapy of BRAF mutant melanoma”


Latvian Biomedical Research and Studies Centre launches new project "Understanding the biology of the minimal residual disease after targeted therapy of BRAF mutant melanoma”.

 

 

On 1st March BMC will be launched European Regional Development Fund (ERDF) Operational Programme Growth and Employment 1.1.1 Specific Aid Objective to increase the research and innovative capacity of scientific institutions of Latvia and the ability to attract external financing, investing in human resources and infrastructure Measure 1.1.1.1 “Industry-Driven Research” 2. Selection round.

Understanding the biology of the minimal residual disease after targeted therapy of BRAF mutant melanoma (Project Identification No 1.1.1.1/18/A/099). The project principle investigator is Dr.biol. Dace Pjanova.

About the project: 

Metastatic melanoma, which arises after initially successful targeted therapy, represents a painful problem for medicine and society due to its high mortality. This project will explore the role of the meiotic component imposed by the melanoma-specific driver mutation of the BRAF kinase onto proliferative cycle in the mechanism of resistance to targeted therapy. The aim of this fundamental study is to study the survival mechanism of B-RAF mutant melanoma cells after treatment with B-RAF kinase inhibitors characterising its critical processes and looking for possible new therapeutic targets, attracting new people to the science and increasing the capacity of scientific excellence of BMC.

Quick links



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".